Form 8-K - Current report:
SEC Accession No. 0001213900-25-003492
Filing Date
2025-01-14
Accepted
2025-01-14 17:28:58
Documents
13
Period of Report
2025-01-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0227706-8k_neupho.htm   iXBRL 8-K 27855
  Complete submission text file 0001213900-25-003492.txt   201777

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE neup-20250110.xsd EX-101.SCH 3027
3 XBRL LABEL FILE neup-20250110_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE neup-20250110_pre.xml EX-101.PRE 22367
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0227706-8k_neupho_htm.xml XML 3685
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41157 | Film No.: 25530309
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)